In 2011, Domain Therapeutics signed an exclusive development and licensing agreement with Merck Serono (Division of Merck KGaA, Darmstadt, Germany), to develop metabotropic glutamate receptor 4 (mGluR4) Positive Allosteric Modulator (PAM) drugs targeting Parkinson’s disease and other neurodegenerative diseases.

Domain Therapeutics has contributed optimized compounds that have been developed from its proprietary chemical series. Under the terms of the agreement, the company has received EUR 2 million in upfront payment and research funding, and was eligible for up to EUR 132 million in milestones for the first two products, as well as undisclosed royalties.